Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer CellsTetsuo Tani, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Therapeutics|2015Cited by 63
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Tomoko Betsuyaku, Kenzo Soejima et al.|Lung Cancer|2013Cited by 49
Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cellsKeiko Ohgino, Kenzo Soejima, Hideki Terai et al.|Cancer Science|2020Cited by 13
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Katsuhiko Naoki et al.|Molecular and Clinical Oncology|2017Cited by 10
Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case reportTetsuo Tani, Tomoko Betsuyaku, Katsuhiko Naoki et al.|Molecular and Clinical Oncology|2016Cited by 7